Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WD-1804
- Development stage
- Phase 4
- Lead developer
- Shanghai WD Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WD-1804 is an investigational oral, controlled-release carbidopa + levodopa drug-device combination from WD Pharmaceutical for advanced Parkinson's disease. The product uses the company's UGiPump upper-gastrointestinal retention and drug-delivery technology to prolong upper-GI levodopa absorption and provide a sustained, relatively steady levodopa plasma-concentration profile, intended as a non-invasive alternative to intestinal levodopa infusion approaches such as Duopa. WD Pharmaceutical describes the program as having completed pre-IND meetings with the FDA and planned for an IND submission for Phase I/II development. (en.wdpharma.com)
- Other names
- Carbidopa-Levodopa Oral Controlled-Release Tablets
02
Targets
Beyond the preview
Go deeper on WD-1804.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WD-1804.